These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 24140611

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Preparation and evaluation of palmitic acid-conjugated exendin-4 with delayed absorption and prolonged circulation for longer hypoglycemia.
    Lee J, Lee C, Kim I, Moon HR, Kim TH, Oh KT, Lee ES, Lee KC, Youn YS.
    Int J Pharm; 2012 Mar 15; 424(1-2):50-7. PubMed ID: 22226877
    [Abstract] [Full Text] [Related]

  • 4. Pulmonary administered palmitic-acid modified exendin-4 peptide prolongs hypoglycemia in type 2 diabetic db/db mice.
    Lee J, Lee C, Kim TH, Chi SC, Moon HR, Oh KT, Lee ES, Lee KC, Youn YS.
    Regul Pept; 2012 Aug 20; 177(1-3):68-72. PubMed ID: 22561689
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Long-acting inhalable chitosan-coated poly(lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes.
    Lee C, Choi JS, Kim I, Oh KT, Lee ES, Park ES, Lee KC, Youn YS.
    Int J Nanomedicine; 2013 Aug 20; 8():2975-83. PubMed ID: 23976850
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Synthesis and evaluation of human serum albumin-modified exendin-4 conjugate via heterobifunctional polyethylene glycol linkage with protracted hypoglycemic efficacy.
    Kim I, Kim TH, Ma K, Lee ES, Kim D, Oh KT, Lee DH, Lee KC, Youn YS.
    Bioconjug Chem; 2010 Aug 18; 21(8):1513-9. PubMed ID: 20715855
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Site-specific PEGylated Exendin-4 modified with a high molecular weight trimeric PEG reduces steric hindrance and increases type 2 antidiabetic therapeutic effects.
    Kim TH, Jiang HH, Lim SM, Youn YS, Choi KY, Lee S, Chen X, Byun Y, Lee KC.
    Bioconjug Chem; 2012 Nov 21; 23(11):2214-20. PubMed ID: 23116483
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Exendin-4 improves the oral glucose tolerance in diabetic rats: pancreas regeneration, better function of pancreatic islets, or impaired glucose uptake?
    Strauss A, Moskalenko V, Chodnevskaja I, Timm S, Thiede A, Otto C, Ulrichs K.
    Transplant Proc; 2008 Mar 21; 40(2):533-5. PubMed ID: 18374122
    [Abstract] [Full Text] [Related]

  • 14. In vitro and in vivo evaluation of a once-weekly formulation of an antidiabetic peptide drug exenatide in an injectable thermogel.
    Yu L, Li K, Liu X, Chen C, Bao Y, Ci T, Chen Q, Ding J.
    J Pharm Sci; 2013 Nov 21; 102(11):4140-9. PubMed ID: 24114868
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Exendin-4, a glucagon-like peptide-1 analogue, accelerates diabetic wound healing.
    Roan JN, Cheng HN, Young CC, Lee CJ, Yeh ML, Luo CY, Tsai YS, Lam CF.
    J Surg Res; 2017 Feb 21; 208():93-103. PubMed ID: 27993221
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of chitosan nanoparticles and chitosan hydrogels for vaccine delivery.
    Gordon S, Saupe A, McBurney W, Rades T, Hook S.
    J Pharm Pharmacol; 2008 Dec 21; 60(12):1591-600. PubMed ID: 19000363
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.